Trastuzumab in Peru: current situation and prospects

Home/Reports | Posted 16/01/2026 post-comment0 Post your comment

Action International for Health (AIS) Peru is an organization dedicated to promoting universal access to medicines, vaccines, and other essential health technologies as fundamental components of the right to health. Its work focuses on defending public policies that ensure the availability, accessibility, and rational use of these products, especially in contexts of social and economic vulnerability.

Trastuzumab Herceptin V13D12

The report ‘Trastuzumab in Peru: A Renewed Monopoly’, published in October 2025 by AIS Peru, analyses the situation of trastuzumab, an essential biotech drug for treating of HER2-positive breast cancer.

Following the entry of biosimilars into the market, the price of intravenous trastuzumab fell significantly, reaching a 94% reduction by 2024. However, Roche has obtained patents for a new 600 mg subcutaneous formulation, valid until 2030, which could reestablish a monopoly and increase treatment costs.

The report highlights the need to strengthen competition policies and rigorously evaluate patent applications to avoid unjustified exclusivity that restricts access to health technologies and, consequently, undermines the right to health. 

Related articles
DIGEMID’s 45-day auto-approvals trigger safety warning

Access to biosimilars for cancer treatments in Latin America

Biosimilar regulations perspective in Latin America to improve cancer treatment access

LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Directriz estadounidense para eliminar los estudios comparativos de eficacia de los biosimilares

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Directriz estadounidense para eliminar los estudios comparativos de eficacia de los biosimilares

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2026 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010